Persistence of subcutaneous versus intravenous infliximab in a real-life cohort: A propensity-score matched comparative analysis
Bothorel, L., Laharie, D., Poullenot, F., Gohier, E., Chevrier, C., Berger, A., Zerbib, F., Rivière, P.
Published in Digestive and liver disease (07.10.2024)
Published in Digestive and liver disease (07.10.2024)
Get full text
Journal Article
P805 The persistence of subcutaneous infliximab is equivalent to intravenous form in patients with inflammatory bowel diseases
Bothorel, L, Laharie, D, Poullenot, F, Gohier, E, Chevrier, C, Berger, A, Zerbib, F, Riviere, P
Published in Journal of Crohn's and colitis (24.01.2024)
Published in Journal of Crohn's and colitis (24.01.2024)
Get full text
Journal Article